Cardiovascular Intervention and Therapeutics

, Volume 25, Issue 1, pp 29–39

Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry

  • Takeshi Kimura
  • Takaaki Isshiki
  • Yasuhiko Hayashi
  • Shigeru Oshima
  • Masanobu Namura
  • Hitoshi Nakashima
  • Kazuya Kawai
  • Takahito Sone
  • Ryozo Tatami
  • Taiichiro Meguro
  • Masakiyo Nobuyoshi
  • Kazuaki Mitsudo
Original Article

Abstract

The incidence of surgical procedures after sirolimus-eluting stent (SES) implantation and, more importantly, the rate of perioperative stent thrombosis (ST) and/or other adverse events have not yet been adequately addressed. The incidence and outcome of the surgical procedures after SES implantation were prospectively evaluated in a large-scale multicenter registry of patients undergoing SES implantation. Among 12,824 patients enrolled in the registry, cumulative incidences of surgical procedures were 0.7% at 60 days, 5.1% at 1 year and 14.7% at 3 years. Surgical procedures were performed in 1,430 patients including non-coronary artery bypass graft (CABG) surgery in 1,275 patients and CABG in 189 patients. The incidences of death/myocardial infarction/ST (definite or probable) and ST (definite or probable) at 30 days after surgical procedures were 2.7 and 0.35%, respectively. Surgery performed within 60 days after SES implantation as compared with that performed beyond 60 days was associated with significantly higher incidences of death/myocardial infarction/ST (definite or probable) and ST (definite or probable) at 30 days after surgical procedures (6.4 vs. 2.5%: P = 0.02 and 2.2 vs. 0.23%: P = 0.002, respectively). Surgery within 60 days as well as hemodialysis and small body mass index were independent risk factors of death/myocardial infarction/ST (definite or probable) identified by multivariable analysis. Surgical procedures were required fairly often after SES implantation. The incidences of adverse cardiac events including ST after surgical procedures were acceptably low. Surgery within 60 days after SES implantation carried significantly higher risks as compared with those beyond 60 days.

Keywords

Stent Thrombosis Revascularization Surgery Aspirin 

References

  1. 1.
    Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of non-cardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, et al. Clinical outcome of patients undergoing non-cardiac surgery in the 2 months following coronary stenting. J Am Coll Cardiol. 2003;42:234–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, et al. Major non-cardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv. 2004;63:141–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Reddy PR, Vaitkus PT. Risks of non-cardiac surgery after coronary stenting. Am J Cardiol. 2005;95:755–7.CrossRefPubMedGoogle Scholar
  5. 5.
    McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–19.CrossRefPubMedGoogle Scholar
  8. 8.
    Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–78.CrossRefPubMedGoogle Scholar
  9. 9.
    Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Brilakis ES, Banerjee S, Berger PB. The risk of drug-eluting stent thrombosis with non-cardiac surgery. Curr Cardiol Rep. 2007;9:406–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multi-vessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.CrossRefPubMedGoogle Scholar
  14. 14.
    McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351:2795–804.CrossRefPubMedGoogle Scholar
  15. 15.
    Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thompson IR, Hoeks SE, et al. A clinical randomized trial to evaluate the safety of a non-invasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V pilot study. J Am Coll Cardiol. 2007;49:1763–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Compton PA, Zanker AA, Adesanya AO, Banerjee S, Brilakis ES. Risk of non-cardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol. 2006;98:1212–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, Lee SJ. Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent. Int J Cardiol. 2008;123:353–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, et al. Non-cardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007;49:122–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Brotman DJ, Bakhru M, Saber W, Aneja A, Bhatt DL, Tillan-Marthinez K, et al. Discontinuation of antiplatelet therapy prior to low-risk non-cardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med. 2007;2:378–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Anwaruddin S, Askari AT, Saudye H, Batizy L, Houghtaling PL, Alamoudi M, et al. Characterization of post-operative risk associated with prior drug-eluting stent use. JACC Cardiovasc Interv. 2009;2:542–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Biondi-Zoccai GGL, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Burger W, Chemnitius M, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med. 2005;257:399–414.CrossRefPubMedGoogle Scholar
  24. 24.
    Sonksen JR, Kong KL, Holder R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth. 1999;82:360–5.PubMedGoogle Scholar
  25. 25.
    Komatsu T, Tamai Y, Takami H, Yamagata K, Fukuda S, Munakata A. Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. J Gastroenterol. 2005;40:698–707.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2009

Authors and Affiliations

  • Takeshi Kimura
    • 1
  • Takaaki Isshiki
    • 2
  • Yasuhiko Hayashi
    • 3
  • Shigeru Oshima
    • 4
  • Masanobu Namura
    • 5
  • Hitoshi Nakashima
    • 6
  • Kazuya Kawai
    • 7
  • Takahito Sone
    • 8
  • Ryozo Tatami
    • 9
  • Taiichiro Meguro
    • 10
  • Masakiyo Nobuyoshi
    • 11
  • Kazuaki Mitsudo
    • 12
  1. 1.Department of Cardiovascular of Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Teikyo University HospitalTokyoJapan
  3. 3.Tsuchiya General HospitalHiroshimaJapan
  4. 4.Gunma Prefectural Cardiovascular CenterGunmaJapan
  5. 5.Kanazawa Cardiovascular HospitalKanazawaJapan
  6. 6.National Hospital Organization Kagoshima Medical CenterKagoshimaJapan
  7. 7.Chikamori HospitalKochiJapan
  8. 8.Ogaki Municipal HospitalOgakiJapan
  9. 9.Maizuru Kyosai HospitalMaizuruJapan
  10. 10.Sendai Health HospitalSendaiJapan
  11. 11.Kokura Memorial HospitalKokuraJapan
  12. 12.Kurashiki Central HospitalKurashikiJapan

Personalised recommendations